Holen Sie sich die Stockscreener-App
145.94
1.14%
1.90
Schlusskurs vom Vortag:
$144.04
Offen:
$143.05
24-Stunden-Volumen:
660.39K
Relative Volume:
0.45
Marktkapitalisierung:
$11.77B
Einnahmen:
$8.19B
Nettoeinkommen (Verlust:
$758.19M
KGV:
15.90
EPS:
9.18
Netto-Cashflow:
$1.06B
1W Leistung:
-4.21%
1M Leistung:
+2.69%
6M Leistung:
-26.47%
1J Leistung:
-56.37%
1-Tages-Spanne:
$142.16
$145.99
1-Wochen-Bereich:
$142.16
$153.62
52-Wochen-Spanne:
$125.10
$342.55
Icon Plc Stock (ICLR) Company Profile
Firmenname
Icon Plc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ICLR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
145.70 | 11.96B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
422.25 | 158.50B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
194.64 | 143.82B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
519.71 | 43.48B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.56 | 34.46B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
162.19 | 28.03B | 15.50B | 1.33B | 2.16B | 7.34 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-04-14 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-04-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-09-18 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2023-12-15 | Eingeleitet | Truist | Buy |
| 2023-09-13 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-17 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-01-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-11-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-09-07 | Eingeleitet | UBS | Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-05-24 | Eingeleitet | Guggenheim | Buy |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-09-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-14 | Eingeleitet | Citigroup | Neutral |
| 2021-04-13 | Fortgesetzt | BofA Securities | Neutral |
| 2021-04-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | Eingeleitet | Barclays | Equal Weight |
| 2021-03-01 | Hochstufung | UBS | Neutral → Buy |
| 2021-02-26 | Hochstufung | Truist | Hold → Buy |
| 2020-07-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-04-20 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Hold |
| 2020-01-27 | Herabstufung | SunTrust | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-09-23 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | Hochstufung | UBS | Sell → Neutral |
| 2019-01-25 | Hochstufung | Mizuho | Neutral → Buy |
| 2018-10-26 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-10-09 | Eingeleitet | UBS | Sell |
| 2018-04-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-15 | Bestätigt | Mizuho | Neutral |
| 2018-01-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-10-27 | Bestätigt | Barclays | Equal Weight |
| 2017-09-11 | Eingeleitet | BofA/Merrill | Buy |
| 2017-07-31 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-27 | Bestätigt | Mizuho | Neutral |
| 2017-06-29 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Icon Plc Aktie (ICLR) Neueste Nachrichten
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
ICON’s Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report - Business Wire
ICON Dominates Phase 1 Clinical Trials: Outperforms All Major CROs in 17 Key Metrics - Stock Titan
Do You Believe in the Upside Potential of ICON PLC (ICLR)? - Insider Monkey
Clinical Trial Investigative Site Network Market Top Players - openPR.com
Launch Your Career as a Life Science Intern at ICON, Apply Now! - BioTecNika
Icon (ICLR) Gets a Buy from Leerink Partners - The Globe and Mail
Truist Financial Maintains Icon PLC(ICLR.US) With Buy Rating, Announces Target Price $187 - 富途牛牛
ICON plc stock price target lowered to $187 at Truist Securities - Investing.com Nigeria
ICON plc stock price target lowered to $187 at Truist Securities By Investing.com - Investing.com South Africa
WCM Investment Management, LLC Significantly Reduces Stake in Icon PLC - GuruFocus
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability - 01net
ICON and Its Employees Recognised as Clinical Research Industry - GuruFocus
Should You Hold ICON PLC (ICLR)? - MSN
Will ICON PLC (ICLR) Benefit from R&D Spending? - Insider Monkey
Barclays Sticks to Their Hold Rating for Icon (ICLR) - The Globe and Mail
ICON plc Schedules Q2 2025 Earnings Call - TipRanks
ICON Announces Q2 2025 Earnings Call - AInvest
ICON plc Reports Strong Interim Financial Results for Early 2025 - TipRanks
Robert W. Baird Maintains Hold Rating for Icon (ICLR) with $150 Price Target - AInvest
Medical Device Regulatory Affairs Market Top PlayersICON, - openPR.com
ICON plc Announces 2025 AGM and Key Resolutions - TipRanks
Icon PLC (ICLR) Shares Up 3.47% on Jun 6 - GuruFocus
Regulatory Affairs Outsourcing Market Analysis Report 2025: Globalization of Biopharmaceutical and Medical Device Companies Bolster Growth - GlobeNewswire Inc.
ICON Public Limited (NASDAQ:ICLR) Short Interest Up 25.4% in May - Defense World
Icon PLC (ICLR) Stock Price Up 4.49% on Jun 4 - GuruFocus
ICON at William Blair Conference: Strategic Focus Amid Challenges - Investing.com
ICON Becomes the First Large Clinical Research Organization to Fully Integrate Medidata Clinical Data Studio, Streamlining Data Management and Review - mx.advfn.com
Here's Why You Should Retain ICLR Stock in Your Portfolio Now - TradingView
Icon PLC (ICLR) Down 9.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
ICON plc to Present at the William Blair 45th Annual Growth Stoc - GuruFocus
ICON plc to Present at Annual Growth Stock Conference By Investing.com - Investing.com South Africa
ICLR December 2026 Options Begin Trading - Nasdaq
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference - BioSpace
ICON plc to Present at Annual Growth Stock Conference - Investing.com
ICON plc to Present at William Blair Growth Stock Conference - TipRanks
ICON’s SWOT analysis: cro stock faces headwinds amid potential rebound - Investing.com
ICON Life Science Internship For BSc & MSc – Applications Closing Soon! Hurry! - BioTecNika
Redburn Atlantic Adjusts Icon (ICLR) Price Target Amid Market Uncertainty | ICLR Stock News - GuruFocus
ICON Plc stock hits 52-week low at $127.51 amid market challenges By Investing.com - Investing.com South Africa
ICON Plc stock hits 52-week low at $127.51 amid market challenges - Investing.com Nigeria
ICON releases its ICON Cares 2024 Report | ICLR Stock News - GuruFocus
ICON releases its ICON Cares 2024 Report - Silicon Canals
ICON Releases ICON Cares 2024 Report Highlighting ESG Achievements - TipRanks
ICON Leads CRO Industry in Sustainability: Achieves 70% GHG Reduction and TIME Recognition - Stock Titan
ICON holds lead as most active CRO, GlobalData finds - The Pharma Letter
Icon (ICLR) Maintains Outperform Rating Amid Price Target Adjustment | ICLR Stock News - GuruFocus
Icon (ICLR) Price Target Reduced by Mizuho to $173 | ICLR Stock News - GuruFocus
Finanzdaten der Icon Plc-Aktie (ICLR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):